## Susanne Wieschowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7242253/publications.pdf

Version: 2024-02-01

15 papers	309 citations	9 h-index	996975 15 g-index
16	16	16	468
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Specific T cells targeting <i>Staphylococcus aureus</i> fibronectinâ€binding protein 1 induce a type 2/type 1 inflammatory response in sensitized atopic dermatitis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1245-1253.	5.7	13
2	Results dissemination from completed clinical trials conducted at German university medical centers remained delayed and incomplete. The 2014 –2017 cohort. Journal of Clinical Epidemiology, 2022, 144, 1-7.	5.0	19
3	Web-based survey among animal researchers on publication practices and incentives for increasing publication rates. PLoS ONE, 2021, 16, e0250362.	2.5	3
4	Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies. British Journal of Clinical Pharmacology, 2020, 87, 2723-2731.	2.4	9
5	Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis. BMJ Open, 2020, 10, e034666.	1.9	11
6	Attitudes towards animal study registries and their characteristics: An online survey of three cohorts of animal researchers. PLoS ONE, 2020, 15, e0226443.	2.5	6
7	Result dissemination from clinical trials conducted at German university medical centers was delayed and incomplete. Journal of Clinical Epidemiology, 2019, 115, 37-45.	5.0	42
8	Publication rates in animal research. Extent and characteristics of published and non-published animal studies followed up at two German university medical centres. PLoS ONE, 2019, 14, e0223758.	2.5	29
9	The spectrum of ethical issues in a Learning Health Care System: a systematic qualitative review. International Journal for Quality in Health Care, 2018, 30, 161-168.	1.8	27
10	Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a crossâ€sectional study. British Journal of Pharmacology, 2018, 175, 4229-4238.	5.4	19
11	Preclinical efficacy studies in investigator brochures: Do they enable risk–benefit assessment?. PLoS Biology, 2018, 16, e2004879.	5.6	55
12	Tracking the timely dissemination of clinical studies. Characteristics and impact of 10 tracking variables. F1000Research, 2018, 7, 1863.	1.6	4
13	Ethics Reporting in Biospecimen and Genetic Research: Current Practice and Suggestions for Changes. PLoS Biology, 2016, 14, e1002521.	5.6	2
14	α-NAC–Specific Autoreactive CD8+ T Cells in Atopic Dermatitis Are of an Effector Memory Type and Secrete IL-4 and IFN-γ. Journal of Immunology, 2016, 196, 3245-3252.	0.8	42
15	Animal Study Registries: Results from a Stakeholder Analysis on Potential Strengths, Weaknesses, Facilitators, and Barriers. PLoS Biology, 2016, 14, e2000391.	5.6	24